Grafalon (rabbit anti-T-lymphocyte globulin) / Mundipharma, NeoPharm, Zydus Lifesci - LARVOL DELTA

Epidemiology, risk factors, and outcomes of cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplantation: A retrospective observational single-centre study from western India (ASH 2025) - "While pre-emptive therapy has reduced CMV disease, reactivation remains common, particularly in alternate donor transplants and resource-limited settings where access to newer antivirals like letermovir is limited...Serotherapy type did not impact overall reactivation, but early reactivation was significantly higher with Grafalon vs. Thymoglobulin (90% vs. 33.6%, p<0.001)...Adverse effects included neutropenia (ganciclovir/valganciclovir) and nephrotoxicity (foscarnet/cidofovir)... This single-centre study demonstrates a high CMV reactivation rate (89.7%) in a high-seroprevalence Indian cohort, especially in alternate donor and PTCy-treated patients. While CMV disease was rare due to effective surveillance and pre-emptive therapy, recurrence and antiviral toxicity were common. The type of serotherapy influenced early reactivation risk."

Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Disorders • Immunology • Neutropenia • Transplantation

A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia (ASH 2025) - "The conditioning regimen comprised Bu (0.8 mg/kg every 6 hours, 1 day, weight-adjusted dose for pediatric patients), Flu (30 mg/m²/day, 4 days), Cy (500 mg/m²/day, 4 days), and ATG with Thymoglobulin 2 mg/kg/day, 4 days in 3 patients or ATG-Fresenius 5 mg/kg/day, 4 days in 7 patients. Graft-versus-host disease (GVHD) prophylaxis included cyclosporine and mycophenolate mofetil for all patients, supplemented with either: short-term methotrexate(MTX, +1d 15mg/m², +4d, +8d, +11d 10mg/m², n=2); only CD25 monoclonal antibody(Basiliximab, +3d 20mg, n=1); or both(MTX as above plus Basiliximab, +3d 20mg, n=2; or MTX as above plus Recombinant humanized anti-CD25 monoclonal antibody, +4d, +8d, 1mg/kg, n=5)...Majority of the patients are with good quality of life. Longer follow-up and larger series are needed to evaluate fertility and transplant outcomes with current protocol."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up. (ASH 2025) - "The conditioning regimen was fludarabine and reduced dose intravenous busulfan (FluBu, total6.4-8 mg/kg, n=25), the combination of fludarabine thiotepa, busulfan (TBF, n=61) or other regimens(n=16). Graft-versus-host disease (GVHD) prophylaxis included cyclosporine and methotrexate ormycophenolate. All patients also recieved Anti thymocyte globulin (ATG, Grafalon) during conditioning.With a median follow-up of 5.6 years (range, 0.1-22 years), 56 are alive and 46 have died, 30 of non-relapse causes and 16 of relapse...Azacytidine and venetoclax was the most frequenttreatment for patients relapsing as AML...Allogeneic HSCT can allow long-term survival and possible cure for patients with myelofibrosis. However,long-term survivors are at continuous risk for late relapse and late NRM. For those who are not cured,HSCT may reset the pattern of progression of the myeloproliferative process."

Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelofibrosis • Polycythemia Vera • Transplantation

Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients (ASH 2025) - "Introduction:Rabbit anti-thymocyte globulin (ATG) is a key component of conditioning regimens for patients withaplastic anemia (AA) undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Thymoglobuline (Thymo) is widely regarded as the standard formulation due to its extensive clinicaladoption and inclusion in international guidelines, while Grafalon (Grafa) is also commonly used inclinical practice. In this large, registry-based cohort of AA patients undergoing HSCT, no significant differences wereobserved in OS, GF, GVHD incidence, or GRFS between Thymo and Grafa. However, Grafalon dosageappeared to influence outcomes, particularly with respect to chronic GVHD. These findings support theclinical equivalence of both rabbit ATG formulations in the setting of HSCT and suggest that ATG selectioncan be guided by institutional preference or availability without compromising patient outcomes."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation

Clinical outcome of hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia: A Single center in China (ASH 2025) - "The transplantation methods comprised: haploidentical + cord bloodcomplementary transplantation (CT) (83 cases), haploidentical donor lymphocyte infusion (DLI) + cordblood transplantation (DLI+CB) (19 cases), unrelated donor transplantation (MUD) (27 cases),haploidentical post-transplant cyclophosphamide (PTCy) transplantation (PBSCT) (9 cases), andhaploidentical ex vivo T-cell-depleted (TDH) transplantation (4 cases)...Theconditioning regimen consisted of BU+CY+TT+Flu±ATG-F, with a median PBSC mononuclear cell count of8.6×10^8/kg infused on day 0... HSCT demonstrates significant clinical efficacy and relative safety in treating JMML. Differenttransplantation methods yielded high survival rates, with complementary transplantation showingparticular advantages. TDH transplantation exhibited promising preliminary results, warranting furtherexploration."

Clinical • Clinical data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Myelomonocytic Leukemia • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Juvenile Myelomonocytic Leukemia • Leukemia • Transplantation

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies (ASH 2025) - "Allpatients received haplo-HSCT; pre-transplant disease status was CR (80.0%, n=36) or NR (20.0%, n=9).Conditioning regimens were busulfan (Bu)-cyclophosphamide (Cy) (66.7%), total body Irradiation (TBI)-Cy(17.8%), Bu-fludarabine (flu) (13.3%), or TBI-flu (2.2%). ATG-fresenius (ATG-F) or ATG-thymoglobuline(ATG-T) were used for GVHD prophylaxis... Second transplantation improves survival in patients experiencing relapse following haplo-HSCT who demonstrate HLA loss. Survival outcomes were independent of HLA loss pattern (haplotype vs.locus-specific) or extent (number of loci lost). Poor prognostic factors were pre-transplant NR status andthe use of TBI-based conditioning."

IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Liver Failure • Lymphoma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy for pediatirc relapsed and Refractory Acute lymphoblastic leukemia followed by TCRαβ-depleted haplo-HSCT (ASH 2025) - "The conditioningconsisted of Cyclophosphamide+ Fludarabine+Thiotepa+Busulfan+Anti-human Tlymphocyte immunoglobulin (ATG-F) or Anti-thymocyte globulin (ATG). With a median follow-up of 29 (range, 0.5-53) months, the median time to neutrophil and plateletengraftment was 14 (range, 10–27) and 9 (range, 6–36) days, respectively. Five children experiencedprimary graft failure, four children were rescued after re-conditioning and a secondary haplo-HSCT. Finalengraftment was achieved in 64/65 patients."

Minimal residual disease • Pre-transplantation • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • T Acute Lymphoblastic Leukemia • Transplantation • CD22 • CD34 • CD7

Comparison of anti-human T cell globulins on immune reconstitution and early infections after autologous transplant in patients with multiple sclerosis. (PubMed, Bone Marrow Transplant) - "In this study, we compared immune reconstitution at days 30 and 100 post-transplant in MS patients undergoing AHSCT with cyclophosphamide-based conditioning, combined with in vivo T-cell depletion using either polyclonal rabbit anti-thymocyte globulin (ATG; Thymoglobulin, Genzyme-Sanofi) or rabbit anti-T-lymphocyte globulin (ATLG; Grafalon, Neovii). Although infections resulting in rehospitalization by day 180 were similarly distributed between groups, viral reactivations occurred exclusively in patients receiving ATG. No sign of high grade infectious complications or death was noted."

Journal • Bone Marrow Transplantation • CNS Disorders • Infectious Disease • Multiple Sclerosis • Transplantation • CD8 • IL2RA • IL7R • ISG20

Allogeneic Hematopoietic Stem Cell Transplantation for Adult Metachromatic Leukodystrophy (MLD): A Case Series (ASH 2023) - "82x10 6 CD34+/kg after a reduced intensity conditioning regime with Fludarabine (150 mg/m²) and Treosulfane (10 or 14 g/m²)...For posttransplant immunosuppression Tacrolimus, Methotrexate, Mycophenolate mofetil or Anti-thymocyte globulin (ATG, Grafalon®, Neovii 10 mg/kg) were used...Based on this experience and previously reported cohorts in juvenile and infantile MLD allo-HCT should be thus also considered as a therapeutic option for adult patients with MLD. Longer clinical follow-up, higher patient numbers and ultimately a prospective randomised trial containing an untreated group would be needed to evaluate allo-HCT as a treatment option for adult MLD."

Clinical • Alzheimer's Disease • Ataxia • Bone Marrow Transplantation • CNS Disorders • Cognitive Disorders • Dermatology • Gene Therapies • Graft versus Host Disease • Hepatology • Immunology • Inflammation • Metabolic Disorders • Movement Disorders • Transplantation • CD34

Haploidentical Aß T Cell Depleted HSCT Represents an Alternative Treatment Option in Pediatric and Adult Patients with Sickle Cell Disease (SCD) (ASH 2023) - P2 | "After exchange transfusion, almost identical conditioning regimens consisting of treosulfan, thiotepa, fludarabine (FTT) and ATG-Grafalon were applied in almost all pts, with the only difference in the timing of ATG (upfront in T-haplo-HSCT, prior to day 0 in MSD-HSCT)...The last fatality occurred in 2020 with now 16 additional pts being transplanted safely, not least also because of a consistent letermovir prophylaxis... The safety and efficacy data of this pilot series of T-haplo-HSCT in SCD reveal that T-haplo-HSCT in advanced stage pediatric and adult SCD patients lacking a MSD is feasible. However, diligent viral monitoring and early treatment of viral reactivation, in particular HHV6 is mandatory as otherwise fatal infections may develop."

Clinical • Acute Respiratory Distress Syndrome • Bone Marrow Transplantation • CNS Disorders • Genetic Disorders • Hematological Disorders • Infectious Disease • Inflammation • Pediatrics • Sickle Cell Disease • Transplantation • CD34

Treosulfan Based Haploidentical Αß T Cell Depleted HSCT Represents a Curative Alternative in Pediatric and Adult Patients with Transfusion Dependent Thalassaemia (ASH 2023) - "All patients received an identical conditioning regimen consisting of treosulfan, thiotepa, fludarabine (FTT) and ATG-Grafalon, with the only difference in the timing of ATG (upfront in T-haplo-HSCT, prior to d0 in MSD-HSCT). Independent of donor availability, graft rejection and iron-overload related organ damage (VOD/SOS) are major pitfalls in transplanting advanced stage TDT patients. Treosulfan demonstrated to be an excellent alternative to busulfan in this setting reflected in the safety and efficacy data of this pilot series. Overall, outcomes of T-haplo-HSCT in TDT are very encouraging with a competitive OS, so that a transplant indication in pediatric and AYA TDT patients lacking a MD is feasible."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Transplant Rejection • Transplantation • CD34

Ptcy Versus High Dose of ATG in HLA-Mismatched Unrelated Stem Cell Transplantation for Hematological Malignancies (ASH 2024) - "Recently, post-transplant cyclophosphamide (PTCY) has emerged as a promising GVHD prophylaxis. Retrospective studies suggest PTCY may offer better outcomes than rabbit anti-thymocyte globulin (ATG), potentially due to lower NRM and GVHD rates...Patients received high-dose ATG (HD group : ATG-T 10 mg/kg or ATG-F 60 mg/kg), low-dose ATG (LD group : ATG-T 5 mg/kg or ATG-F 30 mg/kg), or PTCY (PTCY 50mg/kg at day +3 and +4) as GVHD prophylaxis, along with cyclosporin and methotrexate or mycophenolate mofetil.A total of 155 patients were included (41 in the PTCY group, 93 in the HD group, and 21 in the LD group), with median follow-ups of 15.2, 16.23, and 22.5 months, respectively...However, the PTCY group exhibited lower infection rates and GVHD-related mortality, even if we cannot exclude the impact of more recently introduced anti-infectious prophylaxis such as letermovir. These results suggest that PTCY provides added value as GVHD prophylaxis in MMUD alloSCT."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Transplantation • CD4 • CD8

Favorable Outcomes in Pediatric R/R-ALL Following Immunotherapy with CAR-T and UCB Combined to TCRαβ-Depleted Haplo-HSCT (ASH 2024) - "The conditioning consisted of Cyclophosphamide (1 × 50 mg/kg, days -10, -3 to -2), Fludarabine (1 × 40 mg/m2, days -7 to -4), Thiotepa (2 × 5 mg/kg, day -4), Bu ( total 90 mg/m2, days -7 to -5) , and Anti-human T lymphocyte immunoglobulin (ATG-F) (1 × 15 mg/kg,days -9 to -8 ) or Anti-thymocyte globulin (ATG) (5 mg/kg total, days -9 to -8 ). Summary : These data confirm that TCRαβ-depleted haplo-HSCT is a suitable therapeutic option for children with R/R-ALL. The approach combining TCD haplo-HSCT with CAR-T +/- UCB appeared to result in less TRM, less relapse and favorable OS."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Pediatrics • T Acute Lymphoblastic Leukemia • CD22 • CD34 • CD7

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study (ASH 2024) - P2/3 | "Grafalon® (Neovii) is produced by rabbit immunization with the Jurkat T-cell line, while Thymoglobulin® (Sanofi) is made after the animal immunization with human thymocytes...Conclusion We observed excellent outcome results following serotherapy with both Grafalon and Thymoglobulin in ALL pediatric patients transplanted from 9/10 or 10/10 allelic matched UD conditioned with TBI/etoposide...The frequency of CMV disease after reactivation and EBV reactivation, disease and PTLD was significantly higher after Thymoglobulin. The main outcome measures - OS, EFS, and NRM did not show significant differences between the two treatment groups."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dental Disorders • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Pediatrics • Stomatitis • Transplantation

PEDIATRIC KIDNEY TRANSPLANTATION OUTCOMES: A 15-YEAR EXPERIENCE (2010-2025) FROM A SINGLE CENTER IN SOUTH ASIA (ESPN 2025) - "Regarding immunosuppression, 72.7% of patients received induction therapy with either basiliximab (38.9%), thymoglobulin (31.8%), or ATG Fresenius (1.9%). For maintenance immunosuppression, most patients (87.7%) received tacrolimus/mycophenolate/steroid regimens, with 5.2% on steroid-free protocols and 7.8% on cyclosporine-based regimens... This 15-year experience represents the largest single-center pediatric kidney transplantation cohort in South Asia, demonstrating exceptional outcomes despite resource limitations. This study establishes regional benchmarks and provides a sustainable model for developing pediatric transplant programs in resource-constrained settings."

Clinical • Diabetes • Diabetic Nephropathy • Glomerulonephritis • Infectious Disease • Lupus Nephritis • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Pediatrics • Pneumonia • Respiratory Diseases • Transplant Rejection • Transplantation

ENHANCED GVHD PROPHYLAXIS WITH LOW-DOSE GRAFALON® AND POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HAPLOIDENTICAL AND MISMATCHED UNRELATED DONOR STEM CELL TRANSPLANTATION (SIE 2025) - "The combination of low-dose Grafalon® and PTCy appears to be a safe and effective GvHD prophylaxis strategy, demonstrating excellent tolerability with no severe acute or chronic GvHD and without increasing the risks of infection or relapse. Larger prospective studies and longer follow-up are needed to confirm these findings and establish the long-term efficacy of this approach."

Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation • CD4

Quantification of the percentage of lymphocyte-binding components in polyclonal anti-thymocyte/lymphocyte globulin products. (PubMed, J Pharm Biomed Anal) - "The method was replicated six times to assess active ATG in ATG-Fresenius utilizing Jurkat cells, resulting in a coefficient of variation (CV) of 11.05 %...Moreover, the biological activity assay demonstrated a strong correlation between the biological activity of pATG and the percentage of active ATG in the pATG preparation (r = 0.9283). In conclusions, we have developed an absolute quantification method for active ATG, which will facilitate precise pharmacokinetic analysis of active ATG and contribute to improving the potency testing and dosing regimens of ATG."

Journal • Graft versus Host Disease • Immunology

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) (clinicaltrials.gov) - P2 | N=40 | Active, not recruiting | Sponsor: Fred Hutchinson Cancer Center | Trial completion date: Dec 2026 ➔ Mar 2026

Trial completion date • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Complement-mediated Rare Disorders • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Myelodysplastic Syndrome • Neutropenia • Oncology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Thrombocytopenia • Transplantation • GATA2 • HLA-B • HLA-C • HLA-DQB1 • HLA-DRB1

Fixed Low-Dose ATLG in HLA-Matched Transplantation is safe and effective. (PubMed, Transplant Cell Ther) - No abstract available

Journal • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • Transplantation

PARVOVIRUS B19 WITH FEVER/RASH POST ALLO-HSCT: AML CASE REPORT (EHA 2025) - "A 66-year-old male patient, Acute myeloid leukemia in complete remission underwent allogeneic hematopoietic stem cell transplantation.The preconditioning regimen consisted of:TBI(6Gy)/Ara-C(0.5g/m²/d*4d)/DEC(20 mg/m²/d*3d)/FLU (30 mg/m²/d*5d)/Me-CCNU (250 mg/m²*1d)/ATG-F (5 mg/kg/d*4d), The process went smoothly overall.Successful engraftment of leukocytes and platelets was achieved...Dermatology considers pemphigus, Initial screening for herpes viruses in plasma and vesicular fluid secretions was negative(HHV1-8), After 1 week of treatment with application of acyclovir 0.5g q8h,methylprednisolone 8mg q12h,ruxolitinib 5mg q12h,there was no clinical improvement... For patients who have undergone allo-HSCT or are immunocompromised and present with fever accompanied by a rash and a progressive decline in hemoglobin levels, HPV B19 infection should be considered as a potential diagnosis. Plasma HPV B19 monitoring, histopathological examination (likely..."

Case report • Clinical • Acute Myelogenous Leukemia • Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dental Disorders • Dermatology • Dermatopathology • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Xerostomia

A PROSPECTIVE COMPARATIVE STUDY OF ATLG VERSUS ANTI-T LYMPHOCYTE GLOBULIN AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS IN UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (EHA 2025) - "Data regarding the direct comparison of anti-T lymphocyte globulin (ATG) and Grafalon (ATLG) as GvHD prophylaxis in unrelated allo-HCT are limited...Six patients (12.5%) in the ATLG arm and 10 (22.2%) in ATG underwent post-infusion cyclophosphamide administration.The median follow-up period was 8 (4.5-15.5) months... In our analysis, the OS and DFS of these patients were higher in comparison to the rest of allo-HCT recipients. Thus, ATLG is shown as a safe and efficient agent for GvHD prophylaxis."

Clinical • Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Oncology • Transplantation

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DIAMOND-BLACKFAN ANEMIA: FAVORABLE OUTCOMES FROM A SINGLE CENTER (EHA 2025) - "Myeloablative conditioning regimens included cyclophosphamide, fludarabine, thiotepa, busulfan, and ATG-F/ATG. Allo-HSCT is an effective curative therapy for DBA. In the absence of HLA-matched donors, haploidentical transplantation from non-carrier relatives is feasible. TCRαβ+ T-cell-depleted protocols significantly shorten engraftment time, reduce risks, and demonstrate excellent outcomes."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Oncology • Pediatrics • Rheumatology • Transplantation • RPL11 • RPL5 • RPS26

COMPARISON OF DIFFERENT DOSES OF RABBIT ANTI-THYMOCYTE GLOBULIN (ATG-T) AND ANTI-T-LYMPHOCYTE GLOBULIN (ATLG) IN TBI-BASED MYELOABLATIVE CONDITIONING FOR HAPLOIDENTICAL TRANSPLANTATION IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS (EHA 2025) - "Background: Rabbit anti-thymocyte globulin (ATG-T, Sanofi) and anti-T-lymphocyte globulin (ATLG, Grafalon) are widely used for graft-versus-host disease (GVHD) prophylaxis in haploidentical hematopoietic stem cell transplantation (HID-HSCT). In the context of TBI-based MAC for ALL patients undergoing HID-HSCT,Although the higher ATG-T dose was linked to increased CMV/EBV viremia, PTLD, and GVHD compared to ATLG, its overall post-transplant efficacy appears optimal—likely due to the elevated NRM observed with the lower ATG-T dose and the higher CIR associated with ATLG. These findings offer valuable guidance for optimizing ATG formulation and dosing for GVHD prophylaxis in HID-HSCT, supporting more personalized treatment strategies for ALL patients."

Clinical • Preclinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Transplantation

COMPARISON OF THYMOGLOBULIN® VS GRAFALON® AS INDUCTION TREATMENT IN KIDNEY TRANSPLANTATION WITH MAASTRICHT TYPE III DONOR (ERA 2025) - "The two most commonly used drugs are Thymoglobulin® and Grafalon®, both rabbit antithymocyte globulins, although they have different antigenic profiles and antibody concentrations. These results suggest that Grafalon® and Thymoglobulin® are comparable in terms of efficacy and safety, with a more favourable haematological profile for Grafalon® in low- immunological-risk KT recipients. However, further studies are needed to confirm these findings."

Cardiovascular • Cytomegalovirus Infection • Infectious Disease • Transplant Rejection • Transplantation

Can ALC be used to optimise ATLG dose inkidney transplant patients ? (ERA 2025) - " The present is a prospective observational study conducted in kidney transplant department of tertiary care centre .As per protocol,40 KTR of intermediate risk group were given dynamic ATLG-Grafalon dosing as induction agent along with standard triple immunosuppressive therapy.Patients with high and low immunological risk were excluded.As per dynamic dosing,the KTR received first dose (3 mg/kg) on the day of transplant .Subsequent doses were determined according to ALC.The ATLG was targeted to keep the mean ALC< 500.The patients were followed up for infections and incidences of acute rejection till 3 months.A comparison of graft outcome, rejections and infections between 40 KTR receiving dynamic Grafalon dosing was done with historical data of 27 KTR who received standard Grafalon dosing (8 mg/kg)... The present study suggests that ALC can be used as a simple bedside tool in optimising the dosage of induction agent in KTR. Reduced dosage of ATLG decreases the risk of..."

Clinical • Infectious Disease • Transplant Rejection • Transplantation